Aradigm Corporation (NASDAQ:ARDM) is set to release its earnings data before the market opens on Tuesday, August 8th. Analysts expect Aradigm Corporation to post earnings of ($0.30) per share for the quarter.

Aradigm Corporation (NASDAQ:ARDM) last posted its earnings results on Monday, May 15th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.18. Aradigm Corporation had a negative return on equity of 665.03% and a negative net margin of 1,515.94%. The company had revenue of $1.69 million for the quarter. On average, analysts expect Aradigm Corporation to post $-1.45 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aradigm Corporation (NASDAQ ARDM) opened at 1.13 on Monday. The firm’s market cap is $16.73 million. Aradigm Corporation has a 52-week low of $0.78 and a 52-week high of $7.19. The stock has a 50 day moving average price of $1.39 and a 200 day moving average price of $1.54.

Separately, Zacks Investment Research lowered shares of Aradigm Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, May 23rd.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at

Aradigm Corporation Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Earnings History for Aradigm Corporation (NASDAQ:ARDM)

Receive News & Stock Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related stocks with our FREE daily email newsletter.